Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevance lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), that demonstrated significant and clinically meaningful efficacy in a 135-patient Phase 2 study in patients with Parkinson's disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify highly selectively expressed, novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering with over 25 brain banks and evaluating an expanding collection of more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson's disease, Amyotrophic Lateral Sclerosis and Alzheimer's disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/13/23 | $51,000,000 | Series B |
Dementia Discovery Fund Dolby Family Ventures Foresite Capital Gates Frontier GV Lightstone Ventures Takeda Ventures UPMC Enterprises | undisclosed |
| 04/25/24 | $47,000,000 | Series B-1 Extension |
Agent Capital Bioluminescence Ventures Double Point Ventures Gates Frontier GV LifeRock Ventures Lightstone Ventures MQB Partners | undisclosed |
